Forty Seven, Inc. Loss Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Forty Seven, Inc. (“Forty Seven” or the “Company”) (NASDAQ: FTSV) to Gilead Sciences, Inc. (“Gilead”) (NASDAQ: GILD). Under the terms of the merger, Gilead will acquire Forty Seven for $95.50 per share in cash.

The Forty Seven merger investigation concerns whether the Board of Forty Seven breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Gilead is underpaying for Forty Seven shares, thus unlawfully harming Forty Seven shareholders.